Nyhet —
We are proud!
We are a part of the global movement to defeat diarrheal disease. That makes us proud!
https://www.youtube.com/watch?feature=player_embedded&v=80POTZN88Ho
Kontakter
-
Björn Sjöstrand Presskontakt VD bjorn@scandinavianbiopharma.se +46 (0)72 712 51 20
Relaterat innehåll
-
Scandinavian Biopharma announces first patient vaccinated in the age-descending study in Bangladesh
On October 20, we began enrollment of a placebo-controlled Phase I/II trial where our enterotoxigenic Escherichia coli (ETEC) vaccine candidate will be tested for safety and immunogenicity in different age groups, including infants as young as six months of age. The study is being conducted under a US Investigational New Drug Application and will enroll about 450 children.
-
Scandinavian Biopharma and PATH sign amendment to collaborative agreement to develop a vaccine against diarrhoeal disease
Enterotoxigenic Escherichia coli (ETEC) bacteria are responsible each year for around 400 million cases of diarrhoea and hundreds of thousands of deaths in low- and middle-income countries. Scandinavian Biopharma holds global rights to commercialize the product and will support PATH in its goal to make the product affordable and available in low-resource countries.
-
Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries
Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. ETEC bacteria are the primary cause of this disease. ETEC is also a major cause of diarrheal disease among children living in endemic countries. A clinical Phase I study of a novel vaccine against diarrhea caused by ETEC has been successfully completed. All primary endpoints were achieved.
